Evofem Biosciences Inc (EVFM PINK) stock market data APIs
$0.0089
0(0%)
as of April 28, 2025
Evofem Biosciences Inc Financial Data Overview
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. The company's commercial products include PHEXXI, a vaginal gel for the prevention of pregnancy; and SOLOSEC, a single-dose oral antimicrobial agent for the treatment of bacterial vaginosis and trichomoniasis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Prev. Close
0.0089
Open
0.0089
High
0.0089
Low
0.0089
52 wk Range
0.006-0.02
Market Cap
974 K
Shares Outstanding
113 M
Revenue
19 363 K
EPS
-0.0288
Beta
-0.873
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Evofem Biosciences Inc data using free add-ons & libraries
Get Evofem Biosciences Inc Fundamental Data
Evofem Biosciences Inc Fundamental data includes:
- Net Revenue: 19 363 K
- EBITDA: -7 027 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-25
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Evofem Biosciences Inc News
New
Evofem to Participate in the Virtual Investor Summer Spotlight Series
-- Live moderated video webcast with members of Evofem management team on Wednesday, July 12th at 4:00 p.m. ET -- SAN DIEGO, July 6, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) (the ...
Evofem Biosciences Announces Financial Results for the First Quarter of 2023
-- Increased net product revenue 37% in the first quarter of 2023 vs. prior year quarter -- -- Reduced operating expenses 72% -- -- Decreased loss from operations by 88% -- -- Reaffirms path to pos...
Evofem Biosciences Announces Strong Preliminary Results for the First Quarter of 2023
Increased net product revenue more than 35% in the first quarter of 2023 vs. prior year quarter Reduced operating expenses more than 70% Decreased loss from operations more than 85% Reaffirms path ...
Evofem Biosciences Announces 1-for-125 Reverse Stock Split
-- CUSIP number for Evofem will change to 30048L302 on May 18, 2023 -- -- Ticker symbol will change to "EVFMD" for 20 business days, then revert to "EVFM" -- SAN DIEGO, May 17, 2023 /PRNewswire/ -- ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
